Targeting metabolic syndrome: Candidate natural agents

Journal of Diabetes

Volumn 2, Issue 4, 2010, Pages 243-249

  Xia, Xuan ^a   Weng, Jianping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

herb; insulin resistance; metabolic syndrome; natural agent; traditional medicine; Type 2 diabetes

Indexed keywords

ANTHOCYANIN; BERBERINE; CURCUMIN; GENISTEIN; GINSENG EXTRACT; GINSENOSIDE RE; GINSENOSIDE RG 3; GINSENOSIDE RH 2; METFORMIN; MOMORDICA CHARANTIA EXTRACT; NARINGENIN; NATURAL PRODUCT; PLACEBO; RESVERATROL;

CONSTIPATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTHOCYANINS; BERBERINE; CHINA; CURCUMIN; FEMALE; FLAVANONES; GENISTEIN; GINSENOSIDES; HUMANS; MALE; MEDICINE, TRADITIONAL; METABOLIC SYNDROME X; MICE; MOMORDICA CHARANTIA; PHYTOTHERAPY; PLANT PREPARATIONS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; STILBENES;

EID: 78649658091     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2010.00090.x     Document Type: Review

References (75)

1. Watanabe CK,. Study in the metabolism chances induced by administration of guanidine bases. I Influence of injected guanidine hydrochloride upon blood content. J Biol Chem. 1918; 33: 253-65.
2. American Diabetes Association. National standards for diabetes self-management education. Diabetes Care. 2010; 33 (Suppl.): S11-61.
3. Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-101.
4. Kaplan NM,. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989; 149: 1514-20.
5. Zhang Y, Li X, Zou D, et al. Treatment of Type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; 93: 2559-65.
6. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10: 1344-51.
7. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in Type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010; 59: 285-92.
8. Yin J, Xing H, Ye J,. Efficacy of berberine in patients with Type 2 diabetes mellitus. Metabolism. 2008; 57: 712-7.
9. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006; 55: 2256-64.
10. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008; 57: 1414-8.
11. Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009; 296: E812-9.
12. Yin J, Gao Z, Liu D, Liu Z, Ye J,. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008; 294: E148-56.
13. Zhou L, Wang X, Shao L, et al. Berberine acutely inhibits insulin secretion from beta-cells through 3′,5′-cyclic adenosine 5′-monophosphate signaling pathway. Endocrinology. 2008; 149: 4510-8.
14. Yu Y, Liu L, Wang X, et al. Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies. Biochem Pharmacol. 2010; 79: 1000-6.
15. Lu SS, Yu YL, Zhu HJ, et al. Berberine promotes glucagon-like peptide-1(7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 2009; 200: 159-65.
16. Zhang BB, Zhou G, Li C,. AMPK: An emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009; 9: 407-16.
17. Zunino S,. Type 2 diabetes and glycemic response to grapes or grape products. J Nutr. 2009; 139 (Suppl.): S1794-800.
18. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109-22.
19. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of Type 2 diabetes. Nature. 2007; 450: 712-6.
20. González-Rodríguez A, Mas Gutierrez JA, Sanz-González S, Ros M, Burks DJ, Valverde AM,. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes. 2010; 59: 588-99.
21. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes. 2009; 58: 344-51.
22. Orimo M, Minamino T, Miyauchi H, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol. 2009; 29: 889-94.
23. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007; 6: 307-19.
24. Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009; 324: 1289-93.
25. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008; 8: 347-58.
26. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-42.
27. Zhang H, Zhang J, Ungvari Z, Zhang C,. Resveratrol improves endothelial function: Role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol. 2009; 29: 1164-71.
28. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M,. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G833-42.
29. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006; 55: 2180-91.
30. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010; 59: 554-63.
31. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+metabolism and SIRT1 activity. Nature. 2009; 458: 1056-60.
32. Sotaniemi EA, Haapakoski E, Rautio A,. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995; 18: 1373-5.
33. Attele AS, Zhou YP, Xie JT, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002; 51: 1851-8.
34. 2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol. 2008; 22: 186-95.
35. Shang W, Yang Y, Zhou L, Jiang B, Jin H, Chen M,. Ginsenoside Rb1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes. J Endocrinol. 2008; 198: 561-9.
36. Hwang JT, Kim SH, Lee MS, et al. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun. 2007; 364: 1002-8.
37. Kim M, Ahn BY, Lee JS, et al. The ginsenoside Rg3 has a stimulatory effect on insulin signaling in L6 myotubes. Biochem Biophys Res Commun. 2009; 389: 70-3.
38. Xia M, Hou M, Zhu H, et al. Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: The role of the peroxisome proliferator-activated receptor {gamma}-liver X receptor {alpha}-ABCA1 pathway. J Biol Chem. 2005; 280: 36 792-801.
39. Xia M, Ling W, Zhu H, et al. Anthocyanin prevents CD40-activated proinflammatory signaling in endothelial cells by regulating cholesterol distribution. Arterioscler Thromb Vasc Biol. 2007; 27: 519-24.
40. Sasaki R, Nishimura N, Hoshino H, et al. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem Pharmacol. 2007; 74: 1619-27.
41. 2-terminal kinase activation. Biochem Pharmacol. 2008; 75: 1393-401.
42. Qin Y, Xia M, Ma J, et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr. 2009; 90: 485-92.
43. Molokanova E, Kramer RH,. Mechanism of inhibition of cyclic nucleotide-gated channel by protein tyrosine kinase probed with genistein. J Gen Physiol. 2001; 117: 219-34.
44. O'Shaughnessy JA,. Chemoprevention of breast cancer. JAMA. 1996; 275: 1349-53.
45. Fu Z, Zhang W, Zhen W, et al. Genistein induces pancreatic {beta}-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinology. 2010; 151: 3026-37.
46. Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA,. Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway. Diabetes. 2006; 55: 1043-50.
47. Penza M, Montani C, Romani A, et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology. 2006; 147: 5740-51.
48. Liu D, Jiang H, Grange RW,. Genistein activates the 3′,5′- cyclic adenosine monophosphate signaling pathway in vascular endothelial cells and protects endothelial barrier function. Endocrinology. 2005; 146: 1312-20.
49. Cho TM, Peng N, Clark JT, et al. Genistein attenuates the hypertensive effects of dietary NaCl in hypertensive male rats. Endocrinology. 2007; 148: 5396-402.
50. Villa P, Costantini B, Suriano R, et al. The differential effect of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women: Relationship with the metabolic status. J Clin Endocrinol Metab. 2009; 94: 552-8.
51. Morton MS, Arisaka O, Miyake N, et al. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr. 2002; 132: 3168-71.
52. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K,. Determination of lignans and isofavonoids in human female plasma following dietary supplementation. J Endocrinol. 1994; 142: 251-9.
53. Morton MS, Chan PS, Cheng C, et al. Lignans and isofavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong and the United Kingdom. Prostate. 1997; 32: 122-8.
54. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S,. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br J Nutr. 2009; 102: 1703-8.
55. Chan LL, Chen Q, Go AG, Lam EK, Li ET,. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr. 2005; 135: 2517-23.
56. Tan MJ, Ye JM, Turner N, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol. 2008; 15: 263-73.
57. Chen Q, Chan LL, Li ET,. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr. 2003; 133: 1088-93.
58. Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR,. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr. 2005; 135: 702-6.
59. Ooi CP, Yassin Z, Hamid TA,. Momordica charantia for Type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; 2: CD007845.
60. Dans AM, Villarruz MV, Jimeno CA, et al. The effect of Momordica charantia capsule preparation on glycemic control in Type 2 diabetes mellitus needs further studies. J Clin Epidemiol. 2007; 60: 554-9.
61. Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002; 76: 560-8.
62. Allister EM, Borradaile NM, Edwards JY, Huff MW,. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes. 2005; 54: 1676-83.
63. Mulvihill EE, Allister EM, Sutherland BG, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes. 2009; 58: 2198-210.
64. Borradaile NM, De Dreu LE, Huff MW,. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes. 2003; 52: 2554-61.
65. Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW,. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res. 2008; 49: 2218-29.
66. Ghanim H, Mohanty P, Pathak R, Chaudhuri A, Sia CL, Dandona P,. Orange juice or fructose intake does not induce oxidative and inflammatory response. Diabetes Care. 2007; 30: 1406-11.
67. Morimoto T, Sunagawa Y, Kawamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008; 118: 868-78.
68. Feng B, Chen S, Chiu J, George B, Chakrabarti S,. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab. 2008; 294: E1119-26.
69. Weisberg SP, Leibel R, Tortoriello DV,. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008; 149: 3549-58.
70. Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S,. Transcriptional co-activator p300 regulates glucose induced gene expression in the endothelial cells. Am J Physiol Endocrinol Metab. 2010; 298: E127-37.
71. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S,. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition. 2009; 25: 964-72.
72. Vuksan V, Stavro MP, Sievenpiper JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in Type 2 diabetes. Diabetes Care. 2000; 23: 1221-6.
73. Kuriyan R, Rajendran R, Bantwal G, Kurpad AV,. Effect of supplementation of Coccinia cordifolia extract on newly detected diabetic patients. Diabetes Care. 2008; 31: 216-20.
74. Ludvik B, Neuffer B, Pacini G,. Efficacy of Ipomoea batatas (caiapo) on diabetes control in Type 2 diabetic subjects treated with diet. Diabetes Care. 2004; 27: 436-40.
75. Stone R,. Lifting the veil on traditional Chinese medicine. Science. 2008; 319: 709-10.